Agios Pharmaceuticals Inc. (AGIO-Q)
NASDAQ:AGIO
34.33
0.75
(2.23%) 1d
Financials
Technical Analysis
Buy, Sell or Hold?
Related posts
Nervous markets await Nvidia
This summary was created by AI, based on 3 opinions in the last 12 months.
Agios Pharmaceuticals Inc. (AGIO) has received mixed reviews from experts regarding its investment potential. Following a decline in stock price, one expert has recommended covering a previous position due to a loss of 19.8%. However, another analyst continues to endorse the company, highlighting its promising pipeline of cancer treatment products expected to become commercial in the upcoming year, with strong potential for cash flow growth. AGIO's trading metrics show it at 3x earnings and 1.2x book value, alongside a notable ROE of 57%. Recommendations include setting stop-loss measures while aiming for price increases, reflecting a belief in its upside potential despite recent market performance. Analysts' price targets suggest potential for significant gains, reinforcing the company's favorable outlook in the biopharma sector.
Premium contentOur PAST TOP PICK with AGIO has triggered its stop at $25. To remain disciplined, we recommend covering the position at this time. This will result in a net investment loss of 23%, when combined with our previous guidance.
Premium contentWe reiterate AGIO as a TOP PICK. The developer of cancer treatment drugs expects two more products to go commercial over the next year- each with the potential to grow cash flows substantially. It trades at 3x earnings, 1.2x book and supports and supports a robust 57% ROE. We recommend trailing up the stop (from $21) to $25, looking to achieve $41 — upside potential of 28%. Yield 0%
(Analysts’ price target is $54.57)Premium contentAGIO is a biopharma company focusing on various cancer treatments. It continues to advance its pipeline of new rare disease treatments include one for anemia blood disorder. It has recently sold a royalty for one of its drugs that is increasing cash reserves dramatically. We like that it trades at 3x earnings, 1.2x book and supports a ROE of 53%. We recommend setting a stop-loss at $21, looking to achieve $43 -- upside potential of 28%. Yield 0%
(Analysts’ price target is $57.00)- «
- ‹
- 1
- ›
- »
Agios Pharmaceuticals Inc.(AGIO-Q) Rating
Ranking : 4 out of 5
Bullish - Buy Signals / Votes : 1
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 1
Agios Pharmaceuticals Inc.(AGIO-Q) Frequently Asked Questions
What is Agios Pharmaceuticals Inc. stock symbol?
Agios Pharmaceuticals Inc. is a American stock, trading under the symbol AGIO-Q on the NASDAQ (AGIO). It is usually referred to as NASDAQ:AGIO or AGIO-Q
Is Agios Pharmaceuticals Inc. a buy or a sell?
In the last year, 1 stock analyst published opinions about AGIO-Q. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Agios Pharmaceuticals Inc..
Is Agios Pharmaceuticals Inc. a good investment or a top pick?
Agios Pharmaceuticals Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Agios Pharmaceuticals Inc..
Why is Agios Pharmaceuticals Inc. stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Agios Pharmaceuticals Inc. worth watching?
1 stock analyst on Stockchase covered Agios Pharmaceuticals Inc. In the last year. It is a trending stock that is worth watching.
What is Agios Pharmaceuticals Inc. stock price?
On 2025-06-06, Agios Pharmaceuticals Inc. (AGIO-Q) stock closed at a price of $34.33.
AGIO is a mid-sized pharma company with a long pipeline of projects continuing to advance towards commercialization -- including one for sickle cell. It trades at 3x earnings, 1.2x book and supports a robust 60% ROE. We like that cash reserves are growing, while product expenses increase. We recommend setting a stop-loss at $24, looking to achieve $39 -- upside potential of 28%. Yield 0%
(Analysts’ price target is $52.43)